title: [Expression of epidermal growth factor receptor (EGFR) in ovarian carcinoma stage III-IV].
abstract: Hyperexpression of epidermal growth factor receptor (EGFR) is often identified as unfavorable prognosis for different epithelial cancers. The study was concerned with an attempt of establishing a relationship between EGFR expression, on the one hand, and patient's clinico-morphological status, prognosis and efficacy of chemotherapy for stage III-IV serous ovarian carcinoma, on the other. EGFR hyperexpression predominated in advanced aggressive tumors and involved a significantly shorter period preceding tumor progression. Similarly, overall survival median in patients with EGFR hyperexpression (21+/-4 months) appeared lower than without it (42+/-8 months). In serous ovarian carcinoma stage III-IV, EGFR hyperexpression should be considered sufficient for prognosis of chemotherapy efficacy, pre-progression time and survival.
authors.forename: E V
authors.initials: EV
authors.lastname: Stepanova
authors.forename: I N
authors.initials: IN
authors.lastname: Polushkina
authors.forename: A A
authors.initials: AA
authors.lastname: Perevoshchikov
authors.forename: V D
authors.initials: VD
authors.lastname: Ermilova
authors.forename: Ia V
authors.initials: IaV
authors.lastname: Vishnevskaia
authors.forename: A A
authors.initials: AA
authors.lastname: Meshcheriakov
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Baryshnikov
authors.forename: M R
authors.initials: MR
authors.lastname: Lichinitzer
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000473:pathology*; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D015854:Up-Regulation
chemical_list: D066246:ErbB Receptors